RT Journal Article SR Electronic T1 British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic JF Gut JO Gut FD BMJ Publishing Group Ltd and British Society of Gastroenterology SP 984 OP 990 DO 10.1136/gutjnl-2020-321244 VO 69 IS 6 A1 Nicholas A Kennedy A1 Gareth-Rhys Jones A1 Christopher A Lamb A1 Richard Appleby A1 Ian Arnott A1 R Mark Beattie A1 Stuart Bloom A1 Alenka J Brooks A1 Rachel Cooney A1 Robin J Dart A1 Cathryn Edwards A1 Aileen Fraser A1 Daniel R Gaya A1 Subrata Ghosh A1 Kay Greveson A1 Richard Hansen A1 Ailsa Hart A1 A Barney Hawthorne A1 Bu'Hussain Hayee A1 Jimmy K Limdi A1 Charles D Murray A1 Gareth C Parkes A1 Miles Parkes A1 Kamal Patel A1 Richard C Pollok A1 Nick Powell A1 Chris S Probert A1 Tim Raine A1 Shaji Sebastian A1 Christian Selinger A1 Philip J Smith A1 Catherine Stansfield A1 Lisa Younge A1 James O Lindsay A1 Peter M Irving A1 Charlie W Lees YR 2020 UL http://gut.bmj.com/content/69/6/984.abstract AB The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK, we have rapidly mobilised inflammatory bowel disease (IBD) centres in order that preparations can be made to protect our patients and the clinical services they rely on. This is a novel coronavirus; much is unknown as to how it will affect people with IBD. We also lack information about the impact of different immunosuppressive medications. To address this uncertainty, the British Society of Gastroenterology (BSG) COVID-19 IBD Working Group has used the best available data and expert opinion to generate a risk grid that groups patients into highest, moderate and lowest risk categories. This grid allows patients to be instructed to follow the UK government’s advice for shielding, stringent and standard advice regarding social distancing, respectively. Further considerations are given to service provision, medical and surgical therapy, endoscopy, imaging and clinical trials.